Catechol-O-methyltransferase Val158Met polymorphism is associated with somatosensory amplification and nocebo responses.
A large number of unwanted adverse events and symptoms reported by patients in clinical trials are not caused by the drug provided, since most of adverse events also occur in corresponding placebo groups. These nocebo effects also play a major role in drug discontinuation in clinical practice, negat...
Principais autores: | Laura Wendt, Antje Albring, Sven Benson, Harald Engler, Andrea Engler, Anke Hinney, Winfried Rief, Oliver Witzke, Manfred Schedlowski |
---|---|
Formato: | Artigo |
Idioma: | English |
Publicado em: |
Public Library of Science (PLoS)
2014-01-01
|
coleção: | PLoS ONE |
Acesso em linha: | http://europepmc.org/articles/PMC4164653?pdf=render |
Registros relacionados
-
Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond.
por: Tunbridge, E, et al.
Publicado em: (2006) -
VAL158MET catechol O-methyltransferase polymorphism contributes to the development of preeclampsia
por: Tamara Sljivancanin Jakovljevic, et al.
Publicado em: (2020-10-01) -
Subjective reward processing and catechol-O- methyltransferase Val158Met polymorphism as potential research domain criteria in addiction: A pilot study
por: Nico Rohlfing, et al.
Publicado em: (2022-10-01) -
Human plasma homocysteine levels are associated with the catechol-O-methyltransferase Val158Met polymorphism
por: Tunbridge, E, et al.
Publicado em: (2007) -
Association between the Catechol O-methyltransferase (COMT) Val158met polymorphism and different dimensions of impulsivity.
por: Leandro Fernandes Malloy-Diniz, et al.
Publicado em: (2013-01-01)